Opdivo

I’m writing—for the second time in six months—to share fantastic news:  just hours ago the FDA approved a powerful new immunotherapy for the treatment of cancer. The drug, called Opdivo® (nivolumab), has been making…

Today the FDA announced the approval of the immunotherapy Opdivo® (nivolumab) for the treatment of advanced squamous non-small cell lung cancer (NSCLC), making it the first immunotherapy approved for that indication.…

Now that Opdivo (nivolumab) has been FDA-approved for two cancer types, and potentially more in the coming months, many patients are wondering: what’s next? Bristol-Myers Squibb (BMS), the maker of Opdivo, has put out…

Today, the FDA approved the use of nivolumab (Opdivo)―an anti-PD-1 antibody―to treat classical Hodgkin lymphoma. This is the first checkpoint immunotherapy approved for any type of lymphoma, and CRI is happy to know of…

Day 3 at AACR17 highlighted the importance of immune memory and personalized approaches to improve patient survival Source link

In 2011, Yervoy® (ipilimumab, anti-CTLA-4) became the first FDA-approved checkpoint immunotherapy, after a pivotal phase III clinical trial showed that it increased survival in patients with advanced melanoma. Three…